Catherine Elizabeth Muehlenbein

Catherine Elizabeth Muehlenbein

Auto-generated profile, based on publicly available information

Catherine Elizabeth Muehlenbein

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2018 in The Patient - Patient-Centered Outcomes Research
Verified
Journal Article
Open access
PDF file
SMSuzanne McMullen
Suzanne McMullen
LHLisa M Hess
Lisa M Hess
EKEdward S. Kim
Edward S. Kim
BLBenjamin Levy
Benjamin Levy
MMMohamed Mohamed
Mohamed Mohamed
KWKatherine B. Winfree
Katherine B. Winfree
Introduction Advanced non-small cell lung cancer (NSCLC) is a severe disease with burdensome symptoms and traditionally poor outcomes. The treatment of advance disease is based on chemotherapy, with the recent addition of immunotherapy. Patients who respond to initial treatment can opt to receive maintenance therapy (MT). It is important to understand why patients with advanced NSCLC choose to accept or refuse therapy, and how physician recommendations play into this decision-making process. This study characterized patient and physician decision-making regarding treatment for patients with advanced non-squamous NSCLC in the USA using the example of MT. Methods and Materials This study employed multiple approaches: patient interviews, a patient survey, and a physician survey. Qualitative interviews were conducted among patients who had been offered MT to identify factors influencing treatment decision-making. The patient survey explored the decision-making process and quantified challenges and motivators for receiving MT. The physician survey included a discrete choice experiment to understand the relationship between physician treatment recommendations and patient characteristics. Results Interviewed patients (n = 10) were motivated to receive MT in the hope of extending their lives and being proactive against their cancer, and they anticipated reduced adverse effects compared with first-line therapy. Surveyed patients (n = 77) described several deterrents to receiving therapy; the most prominent was severity of adverse effects, which was an influencing factor for 34% of patients. The major motivator for receiving therapy was the potential to extend life, which influenced 97% of patients. A total of 100 oncologists participated in the physician survey. Patients’ lack of treatment motivation/inconvenience, disease progression, presence of severe renal co-morbidities, and older age decreased the likelihood of physicians recommending the use of MT. Conclusion This study identified challenges and motivators influencing advanced NSCLC patients’ decisions to accept or refuse therapy, as well as patient and disease characteristics associated with physician’s treatment recommendations for MT.

15 February 2023 in Immunotherapy
Verified
Journal Article
Open access
HAHimani Aggarwal
Himani Aggarwal
KBKayOnda Bayo
KayOnda Bayo
YHYimei Han
Yimei Han
CMCatherine Elizabeth Muehlenbein
Catherine Elizabeth Muehlenbein
YZYajun Emily Zhu
Yajun Emily Zhu
JKJong Seok Kim
Jong Seok Kim
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous non-small-cell lung cancer (NSQ-NSCLC) patients that received pembrolizumab plus pemetrexed-plati... Plain language summary What is this article about? KEYNOTE-189 was a research study (i.e., clinical trial) that compared two different combinations of medicine to treat patients with advanced non-s... Tweetable abstract A real-world study demonstrates similar survival benefits as those reported in the KEYNOTE-189 study of pembrolizumab, pemetrexed and platinum. The study also highlights the impo...

1 May 2021 in Lung Cancer
Verified
Journal Article
Open access
EGEdward B. Garon
Edward B. Garon
JAJoachim G. Aerts
Joachim G. Aerts
JKJong Seok Kim
Jong Seok Kim
CMCatherine E. Muehlenbein
Catherine E. Muehlenbein
PPPatrick Marshall Peterson
Patrick Marshall Peterson
SGShirish M. Gadgeel
Shirish M. Gadgeel
This post hoc analysis assessed the safety of pemetrexed and platinum in combination with pembrolizumab, including time-to-onset and time-to-resolution of all-cause any-grade and grade ≥3 adverse events (AEs) and renal AEs. Patient-level data from KEYNOTE-189 were analyzed in the all-subjects-as-treated population (pembrolizumab arm, n = 405; placebo arm, n = 202), and among patients who received ≥5 cycles of pemetrexed (pemetrexed/pembrolizumab/platinum arm, n = 310; pemetrexed/placebo/platinum arm, n = 135). All-cause AEs were selected based on ≥2 % incidence from previously reported KEYNOTE-189 data and included neutropenia, febrile neutropenia, anemia, thrombocytopenia, asthenia, fatigue, dyspnea, diarrhea, nausea, vomiting, pneumonitis, and renal events. Descriptive statistics summarized all-cause AEs. Medians and interquartile ranges were used to examine time-to-onset and time-to-resolution. The data cutoff was November 8, 2017. In both treatment arms, most non-hematologic (nausea, vomiting, diarrhea, and asthenia), and hematologic (febrile neutropenia, thrombocytopenia, and neutropenia) grade ≥3 AEs with ≥2 % incidence had a median time-to-onset within the first 4 cycles, and a median time-to-resolution of within 2 weeks from onset. A small number of AEs had longer median time-to-onset (pneumonitis and fatigue) and median time-to-resolution (pneumonitis, fatigue, acute kidney injury, and anemia). Among patients who received ≥5 cycles of pemetrexed, the incidence of any-grade renal toxicity in the pemetrexed/pembrolizumab/platinum arm was 2.3 % in Cycles 1-4, 4.8 % in Cycles 5-8, 2.6 % in Cycles 9-12, and 2.5 % in Cycles ≥13; and, in the pemetrexed/placebo/platinum arm, 0.7 % in Cycles 1-4, 1.5 % in Cycles 5-8, 1.3 % in Cycles 9-12, and 2.0 % in Cycles ≥13. Pemetrexed/pembrolizumab/platinum has manageable toxicity with longer duration of treatment. While the incidence of renal toxicity was slightly higher in the pembrolizumab combination as compared to pemetrexed, the incidence did not increase in later treatment cycles. These results support the safe use of the KEYNOTE-189 regimen in clinical practice. NCT02578680 (clinicaltrials.gov).

19 October 2018 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
KAKathleen M. Aguilar
Kathleen M. Aguilar
KWKatherine B. Winfree
Katherine B. Winfree
CMCatherine E. Muehlenbein
Catherine E. Muehlenbein
YZYajun Emily Zhu
Yajun Emily Zhu
TWThomas Wilson
Thomas Wilson
ENEric S. Nadler
Eric S. Nadler